Search
for
Sort by
Research 121–150 of 1000+
- Dose-Dependent Increases in Carotid Intima-Media Thickness Associated with Oral Minoxidil but Not Dutasteride in Healthy Young Males: A Randomized Controlled Pharmacological Trial
- Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Is Dihydrotestosterone a Classic Hormone?
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome
- Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis
- Long-Term Effects of COVID-19
- Gender Differences in Response to COVID-19 Infection and Vaccination
- Mendelian randomization studies of testosterone exposure: A systematic review
- Re-Densification Effect of Pressure-Injected Peptide-Hyaluronic Acid Combination on Male Androgenic Alopecia
- Exploring novel management options for alopecia areata
- The Rotterdam Study: objectives and design update
- Feasibility and acceptability of an online multicomponent very low-carbohydrate intervention in young adult women with obesity: a pilot study
- Author response: Effects of lifelong testosterone exposure on health and disease using Mendelian randomization
- Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial
- Assessing medication use patterns among patients with polycystic ovary syndrome at a tertiary care teaching hospital in South Korea: A retrospective study
- Insights into disparities observed with COVID‐19
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
- Peripheral Arterial Disease: Diagnosis and Management
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014)
- The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial